Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans
| Autor: | Wayne C. Drevets, Koen Schruers, Anantha Shekhar, Sander Brooks, Philip L. Johnson, John A. Moyer, Brock T. Shireman, Cathy Bleys, Luc Van Nueten, Bart Remmerie, Diane Nepomuceno, Lebold Terry Patrick, Rob Zuiker, Giacomo Salvadore, Brian Lord, Abigail I. Nash, Christine Dugovic, Kanaka Tatikola, Gabriel E. Jacobs, Pascal Bonaventure |
|---|---|
| Přispěvatelé: | Psychiatrie & Neuropsychologie, RS: MHeNs - R2 - Mental Health |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
STRESS
medicine.drug_class Physiology BLOCKADE Rodentia Pharmacology Anxiolytic Article lcsh:RC321-571 OREXIN/HYPOCRETIN SYSTEM Cellular and Molecular Neuroscience Orexin Receptors Medicine ANXIETY Animals Humans HEALTHY lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry NEURONS Biological Psychiatry business.industry Antagonist Panic Models Theoretical Receptor antagonist SLEEP Orexin Rats Psychiatry and Mental health PROMOTION Anxiogenic Alprazolam Pharmacodynamics Anxiety RAT Orexin Receptor Antagonists medicine.symptom business medicine.drug RESPONSES |
| Zdroj: | Translational Psychiatry Translational Psychiatry, Vol 10, Iss 1, Pp 1-10 (2020) Translational Psychiatry, 10(1). NATURE PUBLISHING GROUP Translational Psychiatry, 10(1):308. Nature Publishing Group |
| ISSN: | 6139-3215 2158-3188 |
| Popis: | Orexin neurons originating in the perifornical and lateral hypothalamic area project to anxiety- and panic-associated neural circuitry, and are highly reactive to anxiogenic stimuli. Preclinical evidence suggests that the orexin system, and particularly the orexin-1 receptor (OX1R), may be involved in the pathophysiology of panic and anxiety. Selective OX1R antagonists thus may constitute a potential new treatment strategy for panic- and anxiety-related disorders. Here, we characterized a novel selective OX1R antagonist, JNJ-61393215, and determined its affinity and potency for human and rat OX1R in vitro. We also evaluated the safety, pharmacokinetic, and pharmacodynamic properties of JNJ-61393215 in first-in-human single- and multiple-ascending dose studies conducted. Finally, the potential anxiolytic effects of JNJ-61393215 were evaluated both in rats and in healthy men using 35% CO2 inhalation challenge to induce panic symptoms. In the rat CO2 model of panic anxiety, JNJ-61393215 demonstrated dose-dependent attenuation of CO2-induced panic-like behavior without altering baseline locomotor or autonomic activity, and had minimal effect on spontaneous sleep. In phase-1 human studies, JNJ-61393215 at 90 mg demonstrated significant reduction (P 2-induced fear and anxiety symptoms that were comparable to those obtained using alprazolam. The most frequently reported adverse events were somnolence and headache, and all events were mild in severity. These results support the safety, tolerability, and anxiolytic effects of JNJ-61393215, and validate CO2 exposure as a translational cross-species experimental model to evaluate the therapeutic potential of novel anxiolytic drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|